Jazz Pharma Closes $1B Senior Notes Offering, Secures New Credit Facility
Ticker: JAZZ · Form: 8-K · Filed: Aug 28, 2024 · CIK: 1232524
| Field | Detail |
|---|---|
| Company | Jazz Pharmaceuticals PLC (JAZZ) |
| Form Type | 8-K |
| Filed Date | Aug 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt-offering, credit-facility, financing
TL;DR
Jazz Pharma raised $1B in debt and got a new $1B credit line. Stronger balance sheet.
AI Summary
On August 27, 2024, Jazz Pharmaceuticals plc announced the closing of its previously disclosed offering of $1.0 billion aggregate principal amount of 5.000% senior notes due 2032. The company also entered into a new $1.0 billion revolving credit facility, which remains undrawn.
Why It Matters
This filing indicates Jazz Pharmaceuticals has successfully raised significant capital through debt financing and secured a substantial credit line, strengthening its financial flexibility for future operations and investments.
Risk Assessment
Risk Level: low — The filing reports on the successful closing of a debt offering and the establishment of a credit facility, which are standard financial transactions with no immediate negative implications.
Key Numbers
- $1.0B — Senior Notes Offering (Capital raised through debt issuance.)
- $1.0B — Revolving Credit Facility (New source of financial flexibility.)
Key Players & Entities
- Jazz Pharmaceuticals plc (company) — Registrant
- $1.0 billion (dollar_amount) — Aggregate principal amount of senior notes
- 5.000% senior notes due 2032 (dollar_amount) — Details of the debt offering
- $1.0 billion (dollar_amount) — New revolving credit facility
- August 27, 2024 (date) — Date of closing and announcement
FAQ
What was the aggregate principal amount of the senior notes offered by Jazz Pharmaceuticals?
Jazz Pharmaceuticals plc closed its offering of $1.0 billion aggregate principal amount of 5.000% senior notes due 2032.
When did Jazz Pharmaceuticals announce the closing of this offering?
The closing of the offering was announced on August 27, 2024.
What is the interest rate on the senior notes due 2032?
The senior notes due 2032 carry an interest rate of 5.000%.
Has Jazz Pharmaceuticals secured any new credit facilities?
Yes, Jazz Pharmaceuticals entered into a new $1.0 billion revolving credit facility.
Is the new revolving credit facility drawn upon?
No, the new $1.0 billion revolving credit facility remains undrawn.
Filing Stats: 658 words · 3 min read · ~2 pages · Grade level 14.9 · Accepted 2024-08-28 14:27:01
Key Financial Figures
- $0.0001 — istered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Mar
Filing Documents
- d886606d8k.htm (8-K) — 22KB
- 0001193125-24-208688.txt ( ) — 144KB
- jazz-20240827.xsd (EX-101.SCH) — 3KB
- jazz-20240827_lab.xml (EX-101.LAB) — 18KB
- jazz-20240827_pre.xml (EX-101.PRE) — 11KB
- d886606d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Neena Patil Name: Neena Patil Title: Executive Vice President and Chief Legal Officer Date: August 28, 2024